İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - meningococcal polysaccharide group c, quantity: 5 microgram; meningococcal polysaccharide group y, quantity: 5 microgram; meningococcal polysaccharide group w135, quantity: 5 microgram; meningococcal polysaccharide group a, quantity: 5 microgram; tetanus toxoid, quantity: 44 microgram - injection, powder for - excipient ingredients: sucrose; trometamol hydrochloride - nimenrix is indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by neisseria meningitidis groups a, c, w-135 and y.

ABD - İngilizce - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (unii: c9r35m8xv6) (haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen - unii:c9r35m8xv6) - haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen 10 ug in 0.5 ml - hiberix is indicated for active immunization for the prevention of invasive disease caused by haemophilus influenzae (h. influenzae) type b. hiberix is approved for use in children aged 6 weeks through 4 years (prior to fifth birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any h. influenzae type b- or tetanus toxoid-containing vaccine or any component of the vaccine is a contraindication to administration of hiberix [see description (11)] . safety and effectiveness of hiberix in children younger than 6 weeks and in children aged 5 to 16 years have not been established.

Bangladeş - İngilizce - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd., vaccine division - bordetella pertussis + diphtheria toxoid + haemophilus influenzae type b conjugated + hepatitis b surface antigen + tetanus toxoid - vaccine - 4 iu + 30 iu + 10 mcg + 10 mcg + 60 iu/.5 ml

Singapur - İngilizce - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (prefilled syringe) diphtheria toxoid; (prefilled syringe) filamentous haemagglutinin; (prefilled syringe) pertussis toxoid; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney); (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1); (prefilled syringe) poliovirus (inactivated) - type 3 (saukett); (prefilled syringe) tetanus toxoid; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein; (vial) tetanus protein (prp-t) - injection, powder, for suspension - (prefilled syringe) diphtheria toxoid min. 20 iu (30 lf)/0.5 ml; (prefilled syringe) filamentous haemagglutinin 25 μg/0.5 ml; (prefilled syringe) pertussis toxoid 25 μg/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney) 29 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1) 7 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 3 (saukett) 26 du/0.5 ml; (prefilled syringe) tetanus toxoid min. 40 iu (10 lf) /0.5 ml; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein 10 μg/0.5 ml; (vial) tetanus protein (prp-t) 18 - 30 μg/0.5 ml

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Malta - İngilizce - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis toxoid, diphtheria toxoid, filamentous haemagglutinin, fha, tetanus toxoid - suspension for injection in pre-filled syringe - diphtheria toxoid filamentous haemagglutinin (fha) 8 µg tetanus toxoid pertussis toxoid 8 µg pertactin 2.5 µg - vaccines

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - haemophilus influenzae type b polysaccharide; conjugate of haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with toxoids

Malta - İngilizce - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - neisseria meningitidis, polysaccharide group, tetanus toxoid - suspension for injection - neisseria meningitidis polysaccharide group c tetanus toxoid - vaccines

Malta - İngilizce - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 3 µg pertussis toxoid 20 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 20 µg fimbriae types 2 and 3 5 µg haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines